Leading the Way on Rare & Serious Diseases

We are a global biotechnology leader focused on serving patients’ needs. Our scientists use the latest technologies to develop and deliver innovative therapies that are used to treat rare and serious conditions, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, chronic inflammatory demyelinating polyneuropathy, hereditary angioedema, and Alpha-1 antitrypsin deficiency, as well as transplantation and critical care.

You are not alone

We are different because our innovations respond to people’s needs, not market size. In fact, one of our therapies treats a condition affecting approximately 300 patients in the U.S. But when you are one of the 300, a therapy to treat your condition may feel impossible to find. We are here to help. Your condition may be rare, but you are not alone. 

We work with patient groups, plasma donors, researchers, physicians, nurses, pharmacists and home healthcare companies to promote quality care, improve patient access to care, expand educational outreach efforts, and affect public healthcare policy. We know and understand our patients better than just about anyone and are proud to offer the broadest range of quality products in the industry, but we never stop innovating. We continue to introduce new innovations that address unmet medical needs or enhance current treatments. We are first and foremost focused on fulfilling our patients' needs.

Partnering With Patient Organizations

CSL Behring collaborates with rare disease patient organizations at the international, regional, national and local levels to promote quality medical care and services and to improve and expand educational and outreach efforts. Through these partnerships, we strive to raise public awareness and to enhance appropriate public policies for rare diseases.

In Europe, CSL Behring partners with EURORDIS, the European Organization for Rare Diseases. EURORDIS is a patient-driven alliance of representatives from patient organizations and others active in the field of rare diseases. EURORDIS’ mission is to build a strong pan-European community of patient organizations and people living with rare diseases, to be their voice at the European level, and -- directly or indirectly -- to fight against the impact of rare diseases on their lives.

eurordis logo

As a Member of the EURORDIS Round Table of Companies (ERTC) at the Emerald level, CSL Behring gave EURORDIS an unrestricted grant to support its communications activities. In addition, CSL Behring also awarded EURORDIS a three-year educational grant for the development of a new European rare diseases policy project. This project is the first European initiative designed to collect patient opinions on rare disease policies. It is intended to build consensus on preferred public health policy scenarios.

In the United States, CSL Behring partners with the National Organization for Rare Disorders (NORD), an umbrella organization of patient advocacy organizations dedicated to individuals with rare diseases. NORD, along with its more than 260 patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services. CSL Behring serves on the NORD Corporate Council, a group of innovative companies who have and are developing therapies for the treatment of rare disorders, which helps to find commonality and discuss legislative activity to ensure the continued development of rare disease therapies. CSL Behring has provided NORD with unrestricted grants in support of their annual Rare Disease Summit and to bolster its government affairs capabilities.  

nord logo

CSL Behring has been recognized by NORD over the years for manufacturing cutting-edge therapies, winning its Industry Innovation Award on multiple occasions, most recently in 2017 for the licensure of IDELVION®, a long-lasting recombinant factor IX therapy for the treatment of hemophilia B.

Rare Disease Day logo

Learn more about Rare Disease Day

CSL Behring supports International Rare Disease Day to raise awareness among policy makers and the public at large regarding the impact of rare diseases on patients' lives.

Learn More
Patients

If you or a loved one is living with a rare or serious disease, see how our products may help.

Learn More
Giving Back

Helping our patient communities is part of our corporate responsibility.

Learn More
Social Responsibility

We act ethically and honestly at all times.

Learn More

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

You have now been added
to the CSL Behring news list